Phaseline

Companies › Enveda Therapeutics

Enveda Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Immunology, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ENV-294–Phase 2Atopic Dermatitis (AD); Asthma; Atopic DermatitisDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07298395ENV-294Phase 2Atopic Dermatitis (AD)ImmunologyDec 2026
NCT07301255ENV-294Phase 2AsthmaRespiratoryDec 2026
NCT07643766ENV-294Phase 2Atopic DermatitisImmunologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Prana Therapies Cumberland Pharmaceuticals ReAlta Life Sciences Avalyn Pharma Toll Biotech Co. Ltd. (Beijing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.